Drug intelligence / Profile preview

propranolol + norfloxacin + VSL#3

Development stage
Unknown
Lead developer
AstraZeneca
Modality
Live Biotherapeutic Products → Microbiome Therapeutics, Small Molecules
Administration
Oral, Rectal, Intravenous, Ophthalmic
01

Overview

This combination refers to the co-administration of three distinct agents: propranolol, norfloxacin, and VSL#3. Propranolol is a non-selective beta-adrenergic receptor blocker, a small molecule pharmaceutical drug used to treat various cardiovascular conditions like hypertension, angina pectoris, and irregular heart rates, as well as non-cardiac indications such as migraine prevention, essential tremors, and anxiety. Norfloxacin is a small molecule fluoroquinolone antibiotic, effective against a broad spectrum of bacterial infections, particularly those affecting the urinary tract, prostate, gastrointestinal system, and eyes. VSL#3 is a high-potency probiotic medical food comprising eight live bacterial strains, including various Lactobacillus, Bifidobacterium, and Streptococcus species. It is used for the dietary management of conditions like irritable bowel syndrome (IBS), ulcerative colitis (UC), and pouchitis, by modulating the gut microbiota and immune response.

Brand names
InderalNoroxinVSL#3
Other names
AY-20694AY20694AY 20694beta-PropranololBetalongEuprovasinProprasylytReducorPropanalolAnaprilinepropranololodl-propranololPropranololum1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanolAY-64043AY64043AY 64043RefChem:6170
02

Targets

Topo IV (Bacterial Topoisomerase IV)DNA gyraseADRB1 (β1)

Beyond the preview

Go deeper on propranolol + norfloxacin + VSL#3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on propranolol + norfloxacin + VSL#3.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call